GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reviva Pharmaceuticals Holdings Inc (NAS:RVPH) » Definitions » Cash Flow from Investing

Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Cash Flow from Investing : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Reviva Pharmaceuticals Holdings Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Reviva Pharmaceuticals Holdings spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Reviva Pharmaceuticals Holdings gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Reviva Pharmaceuticals Holdings Cash Flow from Investing Historical Data

The historical data trend for Reviva Pharmaceuticals Holdings's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reviva Pharmaceuticals Holdings Cash Flow from Investing Chart

Reviva Pharmaceuticals Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
- - - - -

Reviva Pharmaceuticals Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Reviva Pharmaceuticals Holdings Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Reviva Pharmaceuticals Holdings's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Reviva Pharmaceuticals Holdings's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reviva Pharmaceuticals Holdings  (NAS:RVPH) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Reviva Pharmaceuticals Holdings's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Reviva Pharmaceuticals Holdings spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Reviva Pharmaceuticals Holdings's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Reviva Pharmaceuticals Holdings gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Reviva Pharmaceuticals Holdings's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Reviva Pharmaceuticals Holdings spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Reviva Pharmaceuticals Holdings's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Reviva Pharmaceuticals Holdings gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Reviva Pharmaceuticals Holdings's purchase of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Reviva Pharmaceuticals Holdings spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Reviva Pharmaceuticals Holdings's sale of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Reviva Pharmaceuticals Holdings gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Reviva Pharmaceuticals Holdings's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means Reviva Pharmaceuticals Holdings paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Reviva Pharmaceuticals Holdings's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Reviva Pharmaceuticals Holdings paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Reviva Pharmaceuticals Holdings's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means Reviva Pharmaceuticals Holdings paid $0.00 Mil for other investing activities.


Reviva Pharmaceuticals Holdings Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Reviva Pharmaceuticals Holdings's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
N/A
Address
19925 Stevens Creek Boulevard, Suite 100, Cupertino, CA, USA, 95014
Reviva Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, 1) Brilaroxazine (RP5063) which is in clinical development and is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and 2) RP1208.
Executives
Purav Patel director 19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO CA 95014
Narayan Parbhu officer: Chief Financial Officer 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA 95014
Beta Operators Fund, L.p. 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Associates, L.p. 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Partners, Llc 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Associates-r, Lp 10 percent owner 250 WEST 55TH STREET, STE 13D, NEW YORK NY 10019
Parag Saxena director, 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Rahul Nayar 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Tenzing Llc director, 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Laxminarayan Bhat director, 10 percent owner, officer: President and CEO 19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO CA 95014
Leslie D. Funtleyder director C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Marc Cantillon officer: Chief Medical Officer 19925 STEVENS CREEK BLVD., SUITE 100, CUPPERTINO CA 95014
Richard A Margolin director 19925 STEVENS CREEK BLVD, SUITE 100, CUPPERTINO CA 95014
Glazer Capital, Llc 10 percent owner 250 WEST 55TH STREET, SUITE 30A, NEW YORK NY 10019
Paul J Glazer 10 percent owner 250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019